jw van zyl incManufacturing and technology transfer
Development-bank financing into South African vaccine manufacturing: what the contract stack has to carry
A $15m development-bank loan into a Cape Town multi-vaccine facility, alongside a syndicate and five separate technology partners — a structure where the financing, the transfer arrangements and the quality obligations all have to line up.
Verified development
On 24 July 2026 the African Development Bank signed an agreement to provide up to $15 million by way of loan to Biologicals and Vaccines Institute of South Africa Ltd (Biovac).
The African Development Bank states that the financing supports a new multi-vaccine manufacturing facility in Cape Town, with capacity stated at 500 million doses annually and operation expected by 2028.
The African Development Bank states that the syndicate includes the International Finance Corporation, the Human Development Accelerator and the European Investment Bank.
The announcement names Sanofi, the International Vaccine Institute, Biological E Limited, EuBiologics and Bharat Biotech as partners in respect of the vaccines to be produced, which it lists as an oral cholera vaccine, an inactivated polio vaccine, a pneumonia vaccine and a meningitis vaccine.
Why it matters
Manufacturing capacity of this kind is built on several contract families signed at different times, by different teams, under different governing laws. The legal risk is rarely inside any one agreement — it is in the interaction between the financing undertakings, the technology-transfer terms and the regulatory responsibility allocation.
Legal and commercial implications
- A facility of this shape is not one transaction. It is a financing layer, a set of separate technology-transfer and licence arrangements with distinct originators, an offtake or procurement layer, and a quality and regulatory layer — each with its own counterparty.
- Where several transfer partners feed one facility, the recurring problem is the interaction between them rather than the terms of any single agreement: field and territory carve-outs, capacity allocation between products, priority when a shared line is constrained, and whether an obligation owed to a lender can be met without breaching an exclusivity owed to a technology partner.
- Development-finance instruments commonly bring undertakings that reach into operations — reporting, environmental and social conditions, procurement requirements, and restrictions on change of control or disposal. Those undertakings have to be reconciled with commercial agreements that are usually negotiated on separate timelines by separate teams.
- Regulatory responsibility does not follow the money. Whoever holds the manufacturing licence, the marketing authorisation and the quality function carries the regulatory obligations regardless of who financed the facility. The contracts have to allocate that expressly rather than leave it to implication.
Questions a counterparty's own team will need to answer
- Where a transfer arrangement and a financing undertaking conflict, which prevails, and has that ordering been documented rather than assumed?
- Is capacity allocation between products contractually defined, or left to be resolved operationally once the facility is constrained?
- Who holds the marketing authorisation for each product, who is the manufacturer of record, and where do the quality and pharmacovigilance responsibilities sit under each transfer agreement?
- Do the lender undertakings restrict any step the commercial agreements contemplate — sublicensing, capacity sale, change of control or export?
Sources